Interactions between caffeine and cocaine in tests of self-administration

Schenk, Susan; Valadez, Albert A.; Horger, Brian A.; Snow, Steven; Wellman, Paul J.

doi:10.1097/00008877-199404000-00006

Cited by 56 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More specifically, in animals, caffeine can amplify cocaine- (Harland et al 1989;Holloway et al 1985) and nicotine-mediated discriminative effects (Gasior et al 2000;; increase operant responding for cocaine (Kuzmin et al 2000;Schenk et al 1994), nicotine (Shoaib et al 1999), and alcohol (Kunin et al 2000;) and reinstate cocaine-seeking behavior (Green and Schenk 2002;Regier et al 2014;Worley et al 1994). Caffeine has also been shown to interact with the dopaminergic effects of nicotine as reported by Tanda and Goldberg (2000).…”

Section: Discussionmentioning

confidence: 99%

Caffeine, a common active adulterant of cocaine, enhances the reinforcing effect of cocaine and its motivational value

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Caffeine, a common active adulterant of cocaine, enhances the reinforcing effect of cocaine and its motivational value

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In contrast, adenosine receptor antagonists, including caffeine and related methylxanthines, produce psychomotor stimulant effects by enhancing locomotor activity and schedulecontrolled behavior (Schenk et al, 1994;Garrett and Griffiths, 1997;Fredholm et al, 1999). The expression of motor behaviors induced by methylxanthines is largely dependent on dopamine transmission as shown by counteraction of locomotion and turning behavior by either reserpine and cr or by dopamine receptor antagonists (Herrera-Marschitz et al, 1988;Josselyn and Beninger, 1991;Garrett and Holtzman, 1994a;Fenu and Morelli, 1998).…”

Section: Morelli and J Wardasmentioning

confidence: 99%

Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease

Morelli

Wardas

2001

neurotox res

View full text Add to dashboard Cite

The most effective treatment of Parkinson's disease (PD) is, at present, the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA), however a number of disadvantages such as a loss of drug efficacy and severe side-effects (psychoses, dyskinesias and on-off phenomena) limit long-term effective utilisation of this drug. Recent experimental studies in which selective antagonists of adenosine A(2A) receptors were used, have shown an improvement in motor disabilities in animal models of PD. The A(2A) antagonist [7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4,3-e)-1,2,4-triazolo(1,5-c) pyrimidine] (SCH 58261) potentiated the contralateral turning behavior induced by a threshold dose of L-DOPA or direct dopamine receptor agonists in unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats, an effect accompanied by an increase in Fos-like-immunoreactivity in neurons of the lesioned striatum. Likewise, other A(2A) receptor antagonists such as (3,7-dimethyl-1-propargylxanthine) (DMPX), [E-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine] (KF 17837) and [E-1,3-diethyl-8(3,4-dimethoxystyryl-7-methyl-3,7-dihydro-1H-purine-2,6-dione] (KW 6002) antagonized catalepsy induced by haloperidol or reserpine in the rat, whereas in non-human primate models of PD, KW 6002 reduced the rigidity and improved the disability score of MPTP-treated marmosets and cynomolgus monkeys. Moreover, in contrast to L-DOPA, selective A(2A) receptor antagonists administered chronically did not produce dyskinesias and did not evoke tolerance in 6-OHDA and MPTP models of PD. An additional therapeutic potential of adenosine A(2A) antagonists emerged from studies showing neuroprotective properties of these compounds in animal models of cerebral ischemia and excitotoxicity, as well as in the MPTP model of PD. Adenosine A(2A) receptor antagonists by reversing motor impairments in animal models of PD and by contrasting cell degeneration are some of the most promising compounds for the treatment of PD.

show abstract

“…Assim, a presença de sensibilização cruzada entre femproporex e cafeína observada no presente trabalho indica que a exposição à cafeína pode aumentar a vulnerabilidade ao abuso de femproporex. A observação de que a administração intra-peritoneal de cafeína aumenta a auto-administração de cocaína (Schenk et al, 1994) corrobora essa hipótese. O mecanismo pelo qual a administração prévia de cafeína causa sensibilização comportamental ao femproporex pode estar relacionado às ações dessas substâncias no sistema dopaminérgico.…”

Section: Discussionunclassified

Exposição repetida à cafeína aumenta a atividade locomotora induzida pelo femproporex em ratos adolescentes e adultos

Paro

Aizenstein

DeLucia

et al. 2008

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

Interactions between caffeine and cocaine in tests of self-administration

Cited by 56 publications

References 0 publications

Caffeine, a common active adulterant of cocaine, enhances the reinforcing effect of cocaine and its motivational value

Caffeine, a common active adulterant of cocaine, enhances the reinforcing effect of cocaine and its motivational value

Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease

Exposição repetida à cafeína aumenta a atividade locomotora induzida pelo femproporex em ratos adolescentes e adultos

Contact Info

Product

Resources

About